IP Library › Granted Patent US 8,206,715
Granted Patent B2
US 8,206,715 · App. 13/100,990 · Granted Jun 26, 2012

Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

Assignee: Five Prime Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,206,715
App. No.
13/100,990
Granted
Jun 26, 2012
Kind
B2
Abstract

Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.

Claims (6)

1. An isolated antibody comprising a heavy chain comprising the sequence of SEQ ID NO: 39 and a light chain comprising the sequence of SEQ ID NO: 46.

2. An isolated antibody comprising a heavy chain comprising a heavy chain (HC) CDR1 having the sequence of SEQ ID NO: 15, an HC CDR2 having the sequence of SEQ ID NO: 16, and an HC CDR3 having the sequence of SEQ ID NO: 17, and a light chain comprising a light chain (LC) CDR1 having the sequence of SEQ ID NO: 18, a LC CDR2 having the sequence of SEQ ID NO: 19, and a LC CDR3 having the sequence of SEQ ID NO: 20.

3. An isolated antibody comprising a heavy chain comprising the sequence of SEQ ID NO: 53 and a light chain comprising the sequence of SEQ ID NO: 60.

4. The antibody of claim 1 or claim 2 , wherein the antibody is a humanized antibody.

5. The antibody of claim 1 or claim 2 , wherein the antibody is selected from a Fab, an Fv, an scFv, a Fab′, and a (Fab′) 2 .

6. A pharmaceutical composition comprising an antibody of any one of claims 1 to 3 and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2012
From: WONG, JUSTIN; VASQUEZ, MAXIMILIANO
To: FIVE PRIME THERAPEUTICS, INC.
Reel/Frame 027866/0818 →
Continuity (2)
Provisional Application 61331177 · May 4, 2010
Related Publication 20110274683A1 · Nov 10, 2011